Litcius/Paper detail

Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized Trial

Samaher Ashram, Houda Bahig, Aisling Barry, Denise Blanchette, Anders Celinksi, Peter Chung, Johnson Darko, David Donath, Robert Doucet, Abigail Erickson, Meredith Giuliani, Darin Gopaul, Scott Hipwell, Joanna Javor, Joda Kuk, Patricia Lindsay, Barbara Millman, Michael R. Oliver, Andrew Pearce, Catherine Russell, Sashendra Senthi, Toni Vu, Andrew Warner, Stewart Gaede, David A. Palma

2022International Journal of Radiation Oncology*Biology*Physics15 citationsDOI

Topics & Concepts

MedicineSABR volatility modelRandomized controlled trialRadiation therapyRadiosurgeryOncologyInternal medicineVolatility (finance)Stochastic volatilityEconomicsFinancial economicsAdvanced Radiotherapy TechniquesLung Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized Trial | Litcius